2005

Pharmaceutical Sci-Tech

• Seasons Greetings, A. D'Emanuele
• Growth Promotion, Gil Zomber
  • <Possible follow-up(s)>
  • RE: Growth Promotion, Tony Cundell
  • RE: Growth Promotion, Scott Sutton
  • Growth Promotion, Andy Minkevich
  • RE: Growth Promotion, Scott Sutton
• Monitoring storage condition for retention sample (AMC vs RH), Yulianda Farraw
• Re: ISO vs GMP, javadsha varaiya - rsc
  • <Possible follow-up(s)>
  • RE: ISO vs GMP, PB Consultancy
• Assistance with obtaining journal articles that appeared over 10 years ago, Michael Anisfeld
• Anaerobic monitoring, Lritchey
• Tableting Specification Manual, vincent.surjana
• GMP and cliinical trial material, Mark Celeste
  • <Possible follow-up(s)>
  • Re: GMP and cliinical trial material, NORMAN RABIN
  • RE: GMP and cliinical trial material, Post, Ivar
• Anaerobic growth testing, carol_lampe
  • <Possible follow-up(s)>
  • RE: Anaerobic growth testing, Jennifer Muncy
• ISO 17025, Atryzek, Vladimir
  • <Possible follow-up(s)>
  • Re: ISO 17025, Paul G. King
  • RE: ISO 17025, Bob Friedel
  • RE: ISO 17025, Atryzek, Vladimir
  • RE: ISO 17025, Bob Friedel
• Sampling raw materials, Andy Minkevich
  • <Possible follow-up(s)>
  • RE: Sampling raw materials, Tony Cundell
  • Re: Sampling raw materials, Paul G. King
  • Re: Sampling raw materials, Stanley110
• Re: Politicized GMPs?, Joseph T. Piechocki
  • <Possible follow-up(s)>
  • Re: Politicized GMPs?, Michael Brown
• URS, Brooks
  • <Possible follow-up(s)>
  • RE: URS, Les Edwards
  • Re: URS, Jeremy.Court
  • Re: URS, Mark Celeste
• Polysorbate 80 sampling and testing, Andy Minkevich
• Deadly Medicine?, Michael Brown
• Product Bubble point in integrity testing, Saritha Devi Polturi
  • <Possible follow-up(s)>
  • Re: Product Bubble point in integrity testing, h.van doorne
  • Re: Product Bubble point in integrity testing, etiennet
  • Re: Product Bubble point in integrity testing, Jim Tyrrell
  • RE: Product Bubble point in integrity testing, Alan.Moon
• When should we passivate to remove rouge?, Robert Loss
  • <Possible follow-up(s)>
  • RE: When should we passivate to remove rouge?, McConlogue, Liam
  • RE: When should we passivate to remove rouge?, Thomas Peither
  • RE: When should we passivate to remove rouge?, Daryl Roll
  • RE: When should we passivate to remove rouge?, Daryl Roll
  • Re: When should we passivate to remove rouge?, GCampbell
• Moisture Issue with Vacuum Dried Product, finbar oneill
  • <Possible follow-up(s)>
  • RE: Moisture Issue with Vacuum Dried Product, Søren Bogø
  • RE: Moisture Issue with Vacuum Dried Product, Tully, Roger
  • RE: Moisture Issue with Vacuum Dried Product, skachhwaha
  • RE: Moisture Issue with Vacuum Dried Product, Barry Giordano
  • RE: Moisture Issue with Vacuum Dried Product, finbar oneill
• Decimals number of impurity in API, Hiroaki Matsumoto
  • <Possible follow-up(s)>
  • Re: Decimals number of impurity in API, Brian MATTHEWS
  • Re: Decimals number of impurity in API, Jim Tyrrell
  • Re: Decimals number of impurity in API, ravindra goyal
  • Re: Decimals number of impurity in API, himanshu
• Ampoules integrity testing method, Papailiou Nikos
  • <Possible follow-up(s)>
  • Re: Ampoules integrity testing method, etiennet
  • Re: Ampoules integrity testing method, JFolan
• Re: Decimal number of Impurity in API, r.kirsch
• R: Ampoules integrity testing method, Mari, Alberto
• Re: GMPs and Clinical Trial Material, william scruggs
  • <Possible follow-up(s)>
  • RE: GMPs and Clinical Trial Material, Michael Anisfeld
  • RE: GMPs and Clinical Trial Material, Mark Celeste
  • RE: GMPs and Clinical Trial Material, David Perkins
  • RE: GMPs and Clinical Trial Material, Miguel Castellanos
  • RE: GMPs and Clinical Trial Material, Nancy Fulginiti
  • RE: GMPs and Clinical Trial Material, Andrew Minkevich
  • RE: GMPs and Clinical Trial Material, Frank Rauschen
• Antisera and clinical trials, Gil Zomber
• Re: GMPs and CTM, William Scruggs
• SIP requirements for temperature, Chip Schenk
  • <Possible follow-up(s)>
  • RE: SIP requirements for temperature, McConlogue, Liam
  • Re: SIP requirements for temperature, Jim Tyrrell
• Expectations of Sanitation Effectiveness, Robert Rosenlof
• FDA 2656, Rajagopal
• Visual Inspection of uncoated tablets, ravindra goyal
• Cleaning Reagents, Tom Smith
  • <Possible follow-up(s)>
  • Re: Cleaning Reagents, Bob Kirsch
  • Re: Cleaning Reagents, s.langford1
  • Re: Re: Cleaning Reagents, BIREN SONI
• WFI Loop Temp, bens
  • <Possible follow-up(s)>
  • Re: WFI Loop Temp, NORMAN RABIN
  • RE: WFI Loop Temp, Kenyon, David [CNTUS]
  • RE: WFI Loop Temp, Pradeep Chakravarty - Claris
  • RE: WFI Loop Temp, Desjardins Claude
  • RE: WFI Loop Temp, Andrew Minkevich
  • RE: WFI Loop Temp, Scott Sutton
  • RE: WFI Loop Temp, Ogden, Bill
• Environmental Monitoring for Clinical APIs, Cheryl Loomis
  • <Possible follow-up(s)>
  • Re: Environmental Monitoring for Clinical APIs, NORMAN RABIN
• Raw material specifications and process validation, Jean-Philippe Cros
  • <Possible follow-up(s)>
  • Re: Raw material specifications and process validation, Paul G. King
  • Re: Raw material specifications and process validation, Dr Moustsfa Al Shammat
  • Re: Raw material specifications and process validation, BIREN SONI
• Non-Sterile APIs, Miguel Castellanos
  • <Possible follow-up(s)>
  • RE: Non-Sterile APIs, Michael Anisfeld
  • re: Non-Sterile APIs, Ogden, Bill
• Anti-static devices, Connie Hillenbrand
  • <Possible follow-up(s)>
  • Re: Anti-static devices, Bob Kirsch